期刊
ALLERGY
卷 70, 期 7, 页码 727-754出版社
WILEY
DOI: 10.1111/all.12616
关键词
allergic rhinitis; asthma; atopic dermatitis; eosinophilic disorders; food allergy; hymenoptera allergy; urticaria
资金
- EAACI
- Swiss National Science Foundation [PP00P3-128421, PP00P3-150751]
- MINECO
- European Social Fund
- Swiss National Science Foundation (SNF) [PP00P3_128421, PP00P3_150751] Funding Source: Swiss National Science Foundation (SNF)
Biologic agents (also termed biologicals or biologics) are therapeutics that are synthesized by living organisms and directed against a specific determinant, for example, a cytokine or receptor. In inflammatory and autoimmune diseases, biologicals have revolutionized the treatment of several immune-mediated disorders. Biologicals have also been tested in allergic disorders. These include agents targeting IgE; T helper 2 (Th2)-type and Th2-promoting cytokines, including interleukin-4 (IL-4), IL-5, IL-9, IL-13, IL-31, and thymic stromal lymphopoietin (TSLP); pro-inflammatory cytokines, such as IL-1, IL-12, IL-17A, IL-17F, IL-23, and tumor necrosis factor (TNF); chemokine receptor CCR4; and lymphocyte surface and adhesion molecules, including CD2, CD11a, CD20, CD25, CD52, and OX40 ligand. In this task force paper of the Interest Group on Biologicals of the European Academy of Allergy and Clinical Immunology, we review biologicals that are currently available or tested for the use in various allergic and urticarial pathologies, by providing an overview on their state of development, area of use, adverse events, and future research directions.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据